Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

Eli Lilly
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Lisa Winter | Sep 17, 2020
Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.
First Antibody Trial Launched in COVID-19 Patients
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.